ATTO-1310 Yields 82% PP-NRS4 Itch Response at Week 12
At week 12, a single ATTO-1310 dose achieved an 82% PP-NRS4 response in chronic pruritus and improved EASI scores in high-itch AD. Phase 2 trials are planned for 2027.
Topic
Phase 1b Trial
Topic
Topic
Topic
At week 12, a single ATTO-1310 dose achieved an 82% PP-NRS4 response in chronic pruritus and improved EASI scores in high-itch AD. Phase 2 trials are planned for 2027.